Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Phase 2

Completed

Conditions: Primary Central Nervous System Lymphoma
Recurrent/Refractory Secondary Central Nervous System Lymphoma
Lymphoma

Interventions: Drug: Buparlisib (BKM120)

First Posted Date: 2014-11-25

Last Posted Date: 2017-10-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT02301364

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

and more 1 locations

[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer
Localized Prostate Cancer

Interventions: Drug: [18F] DIHYDRO-TESTOSTERONE
Device: PET scan
Device: MRI
Other: Blood draw

First Posted Date: 2014-11-21

Last Posted Date: 2018-08-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT02297386

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

Recruiting

Conditions: Dermatologic Conditions
Cancer

Interventions: Behavioral: Quality of Life (QoL) Assessment

First Posted Date: 2014-11-20

Last Posted Date: 2024-12-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1025

Registration Number: NCT02296450

Locations: 🇺🇸
Memorial Sloan Kettering Suffolk- Hauppauge, Hauppauge, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Not Applicable

Completed

Conditions: Breast Cancer Metastases
HER2 Positive Breast

Interventions: Radiation: 89Zr-trastuzumab
Device: PET/CT scan
Radiation: 89Zr-pertuzumab

First Posted Date: 2014-11-10

Last Posted Date: 2021-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT02286843

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer

Phase 1

Active, not recruiting

Conditions: Endometrial Cancer
Cervical Cancer

Interventions: Radiation: 18F-Fluorodeoxyglucose (18F-FDG)
Device: PET/CT imaging
Device: PET/MRI imaging

First Posted Date: 2014-11-06

Last Posted Date: 2024-07-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 42

Registration Number: NCT02285192

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Phase 1

Terminated

Conditions: Lymphoma
Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Relapsed and Refractory

Interventions: Drug: Mocetinostat

First Posted Date: 2014-11-04

Last Posted Date: 2024-03-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT02282358

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

Phase 1

Completed

Conditions: Head and Neck Squamous Cell Cancer

Interventions: Drug: Cetuximab
Drug: BYL719
Radiation: IMRT (Intensity-Modulated Radiation Therapy)

First Posted Date: 2014-11-04

Last Posted Date: 2021-10-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 16

Registration Number: NCT02282371

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 3 locations

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Metastatic Solid Tumors

Interventions: Biological: Mogamulizumab (KW-0761)

First Posted Date: 2014-11-02

Last Posted Date: 2021-04-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT02281409

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
High Risk Superficial

Interventions: Biological: Bacillus Calmette-Guérin (BCG)

First Posted Date: 2014-11-02

Last Posted Date: 2023-02-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 80

Registration Number: NCT02281383

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 1 locations

Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Radiation: external beam radiation therapy
Radiation: brachytherapy
Behavioral: questionnaires

First Posted Date: 2014-10-31

Last Posted Date: 2024-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT02280356

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy